https://wiki.cam.ac.uk/wiki/crucible/index.php?title=Matt_Segall&feed=atom&action=historyMatt Segall - Revision history2024-03-28T13:53:43ZRevision history for this page on the wikiMediaWiki 1.39.4https://wiki.cam.ac.uk/wiki/crucible/index.php?title=Matt_Segall&diff=645&oldid=prevafb21 at 06:24, 26 August 20112011-08-26T06:24:49Z<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 06:24, 26 August 2011</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new [[design approaches to drug discovery]] that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new [[design approaches to drug discovery]] that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:People]]</ins></div></td></tr>
</table>afb21https://wiki.cam.ac.uk/wiki/crucible/index.php?title=Matt_Segall&diff=289&oldid=prevafb21 at 07:23, 10 August 20112011-08-10T07:23:24Z<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:23, 10 August 2011</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Founder of Optibrium, previously at <del style="font-weight: bold; text-decoration: none;">[[</del>ArQule<del style="font-weight: bold; text-decoration: none;">]]</del>, Matt commissioned a Crucible team to develop new <del style="font-weight: bold; text-decoration: none;">interactive </del>approaches to drug <del style="font-weight: bold; text-decoration: none;">design </del>that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new <ins style="font-weight: bold; text-decoration: none;">[[design </ins>approaches to drug <ins style="font-weight: bold; text-decoration: none;">discovery]] </ins>that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.</div></td></tr>
</table>afb21https://wiki.cam.ac.uk/wiki/crucible/index.php?title=Matt_Segall&diff=288&oldid=prevafb21: Created page with "Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling..."2011-08-10T07:21:53Z<p>Created page with "Founder of Optibrium, previously at <a href="/wiki/crucible/index.php?title=ArQule&action=edit&redlink=1" class="new" title="ArQule (page does not exist)">ArQule</a>, Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling..."</p>
<p><b>New page</b></p><div>Founder of Optibrium, previously at [[ArQule]], Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.</div>afb21